Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 18/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29414900 | 1.00 | ACACB (0.46) | ACACBOPRK1JAK2JAK1TYK2 | |
| SCHEMBL20354188 | 0.85 | ACACB (0.45) | ACACBOPRK1 | |
| SCHEMBL31583655 | 0.84 | OPRK1 (0.44) | ACACBOPRK1 | |
| SCHEMBL20354142 | 0.83 | ACACB (0.46) | ACACBOPRK1 | |
| SCHEMBL30748905 | 0.81 | ACACB (0.45) | ACACBOPRK1 | |
| SCHEMBL24240549 | 0.80 | ACACB (0.50) | ACACBOPRK1 | |
| SCHEMBL17512512 | 0.80 | JAK2 (0.36) | ACACBOPRK1JAK2JAK1TYK2 | |
| SCHEMBL19699382 | 0.80 | OPRK1 (0.37) | ACACBOPRK1JAK2JAK1TYK2 | |
| SCHEMBL18483777 | 0.80 | PLAU (0.39) | OPRK1 | |
| SCHEMBL18483979 | 0.80 | OPRK1 (0.40) | OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814393-B2 | Substituted guanidine compounds | UBE CORPORATION (JP) | 2023-11-14 | — | — | US | disclosed |
| US-11814393-B2 | Substituted guanidine compounds | UBE CORPORATION (JP) | 2023-11-14 | — | — | US | disclosed |
| US-11814393-B2 | Substituted guanidine compounds | UBE CORPORATION (JP) | 2023-11-14 | — | — | US | disclosed |
| US-20220315599-A1 | SUBSTITUTED GUANIDINE COMPOUNDS | UBE CORP (JP) | 2022-10-06 | — | — | US | disclosed |
| US-11396514-B2 | Substituted guanidine compounds | UBE CORPORATION | 2022-07-26 | — | — | US | disclosed |
| EP-3585775-B1 | AZETIDINE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI SA (FR) | 2022-04-06 | — | — | EP | disclosed |
| CN-110114350-B | Substituted guanidine compounds | 宇部兴产株式会社 | 2022-03-04 | — | — | CN | disclosed |
| EP-3564230-B1 | SUBSTITUTED GUANIDINE COMPOUND | UBE INDUSTRIES (JP) | 2022-02-09 | — | — | EP | disclosed |
| CN-107922379-B | Substituted guanidine derivatives | 宇部兴产株式会社 | 2020-11-06 | — | — | CN | disclosed |
| US-10759781-B2 | Substituted guanidine derivatives | UBE INDUSTRIES, LTD. (JP) | 2020-09-01 | — | — | US | disclosed |
| EP-3564230-A1 | SUBSTITUTED GUANIDINE COMPOUND | UBE Industries, Ltd. (JP) | 2019-11-06 | — | — | EP | disclosed |
| US-10392366-B2 | Azetidine compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | SANOFI (FR) | 2019-08-27 | — | — | US | disclosed |
| US-20190152953-A1 | SUBSTITUTED GUANIDINE DERIVATIVES | UBE INDUSTRIES, LTD. (JP) | 2019-05-23 | — | — | US | disclosed |
| US-20190152953-A1 | SUBSTITUTED GUANIDINE DERIVATIVES | UBE INDUSTRIES, LTD. (JP) | 2019-05-23 | — | — | US | disclosed |
| WO-2018153849-A1 | AZETIDINE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI (FR) | 2018-08-30 | — | — | WO | disclosed |
| US-20180237419-A1 | AZETIDINE COMPOUNDS AS GRP119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI (FR) | 2018-08-23 | — | — | US | disclosed |
| WO-2018124179-A1 | SUBSTITUTED GUANIDINE COMPOUND | 宇部興産株式会社 | 2018-07-05 | — | — | WO | disclosed |
| EP-3333163-A1 | SUBSTITUTED GUANIDINE DERIVATIVE | UBE Industries, Ltd. (JP) | 2018-06-13 | — | — | EP | disclosed |
| EP-3333163-A1 | SUBSTITUTED GUANIDINE DERIVATIVE | UBE Industries, Ltd. (JP) | 2018-06-13 | — | — | EP | disclosed |
| WO-2017022861-A1 | SUBSTITUTED GUANIDINE DERIVATIVE | 宇部興産株式会社 | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392366-B2 | Azetidine compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | GPR119, GPR39, GPR139 | ACACB 907/4885OPRK1 1177/4885JAK2 1214/4885 |
| US-10759781-B2 | Substituted guanidine derivatives | GMPS, GUCY1A1, GUCY1A2 | ACACB 4162/4885OPRK1 348/4885JAK2 995/4885 |
| US-20220315599-A1 | SUBSTITUTED GUANIDINE COMPOUNDS | GMPS, PDE3B, GUCY1A2 | ACACB 3375/4885OPRK1 455/4885JAK2 1614/4885 |
| US-11814393-B2 | Substituted guanidine compounds | GMPS, PDE3B, GUCY1A2 | ACACB 3375/4885OPRK1 455/4885JAK2 1614/4885 |
| US-20190152953-A1 | SUBSTITUTED GUANIDINE DERIVATIVES | GMPS, GUCY1A1, GUCY1A2 | ACACB 4162/4885OPRK1 348/4885JAK2 995/4885 |
| US-20180237419-A1 | AZETIDINE COMPOUNDS AS GRP119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | GPR119, GIPR, GPR39 | ACACB 1569/4885OPRK1 1179/4885JAK2 1673/4885 |
| US-11396514-B2 | Substituted guanidine compounds | GMPS, PDE3B, GUCY1A2 | ACACB 3375/4885OPRK1 455/4885JAK2 1614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.